Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Multinational, Noninterventional Study With Certolizumab Pegol in Comparison to Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis

Trial Profile

A Multi-center, Multinational, Noninterventional Study With Certolizumab Pegol in Comparison to Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2019

At a glance

  • Drugs Certolizumab pegol (Primary) ; Adalimumab; Disease-modifying antirheumatics; Etanercept; Golimumab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms NexT
  • Sponsors UCB Pharma SA
  • Most Recent Events

    • 28 Feb 2019 Planned End Date changed from 23 Oct 2020 to 1 Aug 2020.
    • 28 Feb 2019 Planned primary completion date changed from 23 Oct 2020 to 1 Aug 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top